Opportunity in crisis? India's medical device sector eyes post tariffs world
As the US sharpens its trade arsenal under Donald Trump’s second term, the Indian medical device sector has been thrust into the crossfire. With sweeping tariffs signaling a shift from free trade to fierce protectionism, India’s MedTech industry—poised for exponential growth—now faces a critical inflection point.
Experts warn that while US tariff tactics may boomerang, India can’t afford complacency. Fixing domestic gaps and strategically navigating the China factor is now mission-critical to protect its MedTech dreams.
While the "Liberation Day" announcement has been put on hold for 90 days (except for China), the 10 per cent baseline duty has already disrupted the long-standing global economic order based on free trade and open market access. The move is pushing policymakers and industry stakeholders to recalibrate their strategies and explore alternative safe passages.
Ironically, just as India’s medical device sector stands on the cusp of transformative growth—where the US has long been considered the default partner to realize these ambitions—the latest announcements have sent ripples across the industry. Further compounding uncertainty are reports that the ongoing bilateral trade deal negotiations might offer better tariff support for US device exports.
To understand the implications of these developments and the shifting trade winds for India’s MedTech ambitions, ETHealthworld hosted a webinar titled “Tariffs, Trade Winds & the MedTech Dream: Can India Weather the Storm?” The discussion focused on how Indian manufacturers can remain resilient and competitive in a rapidly evolving trade landscape, balancing growth aspirations with regulatory and financial pressures.
